U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N
Molecular Weight 149.2332
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENTERMINE

SMILES

CC(C)(Cc1ccccc1)N

InChI

InChIKey=DHHVAGZRUROJKS-UHFFFAOYSA-N
InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html

Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.31 µM [EC50]
498.0 µM [Ki]
375.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ADIPEX-P

Approved Use

ADIPEX-P® is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors

Launch Date

-3.47241611E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
44.78 ng/mL
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
49.1 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2057.33 ng × h/mL
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2000 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.63 h
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Other AEs: Abdominal pain, Dizziness...
Other AEs:
Abdominal pain (6%)
Dizziness (6%)
Early satiety (6%)
Intermittent headache (6%)
Nausea (6%)
Swollen lips (6%)
Upper respiratory infection (6%)
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Other AEs: Anorexia, Back pain...
Other AEs:
Anorexia (6%)
Back pain (6%)
Chapped lips (6%)
Dry skin (6%)
Dyspepsia (6%)
Early satiety (6%)
Irregular pulse (6%)
Nausea (6%)
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Other AEs: Tachycardia, Hypertension...
Other AEs:
Tachycardia
Hypertension
Visual disorders NEC
Nausea
Insomnia
Anxiety
Sources:
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disc. AE: Amnesia, Judgement impaired...
Other AEs: Disorder sleep, Depression...
AEs leading to
discontinuation/dose reduction:
Amnesia (0.3%)
Judgement impaired (0.3%)
Memory impairment (0.3%)
Paraesthesia (0.3%)
Depression (1%)
Anxiety (0.3%)
Vision blurred (0.3%)
Eye pain (0.3%)
Abdominal pain (0.3%)
Tuberculosis skin test positive (0.3%)
Nephrolithiasis (0.3%)
Other AEs:
Disorder sleep (12.9%)
Depression (8.1%)
Anxiety (9.5%)
Cardiac arrhythmia (4.1%)
Ischemic heart disease (1%)
Disturbance in attention (3.1%)
Memory impairment (2%)
Cognitive disorders (1.4%)
Language disorder (0.3%)
Ocular disorders NEC (4.1%)
Dyskinesias and movement disorders NEC (1.4%)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dizziness 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Intermittent headache 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Swollen lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Upper respiratory infection 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Anorexia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Back pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Chapped lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dry skin 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Dyspepsia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Irregular pulse 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
healthy, 18 - 45 years old
n = 17
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Population Size: 17
Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12
Anxiety
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Hypertension
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Insomnia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Nausea
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Tachycardia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Visual disorders NEC
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
healthy, mean age 30 years
n = 2
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 2
Sources:
Language disorder 0.3%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Abdominal pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Amnesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Anxiety 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Eye pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Judgement impaired 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Memory impairment 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Nephrolithiasis 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Paraesthesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Tuberculosis skin test positive 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Vision blurred 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Ischemic heart disease 1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Depression 1%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Cognitive disorders 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Dyskinesias and movement disorders NEC 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disorder sleep 12.9%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Memory impairment 2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Disturbance in attention 3.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Cardiac arrhythmia 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Ocular disorders NEC 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Depression 8.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Anxiety 9.5%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Co-administed with::
topiramate(92 mg; 1/day)
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
unhealthy, mean age 51.9 years
n = 295
Health Status: unhealthy
Condition: obesity
Age Group: mean age 51.9 years
Sex: M+F
Population Size: 295
Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
weak (co-administration study)
Comment: In the presence of topiramate, phentermine Cmax and AUC0-inf increased 13 and 42%, respectively
Page: 39,38
PubMed

PubMed

TitleDatePubMed
Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices.
2001 Nov-Dec
Pharmacotherapy of obesity: currently marketed and upcoming agents.
2002
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis.
2002
Fen-Phen-noumenon: A mass tort litigation and settlement about to come and go.
2002 Aug
Appetite suppressants and valvular heart disease - a systematic review.
2002 Aug 23
Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
2002 Dec
Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
2002 Dec 1
[Syncope - a systematic overview of classification, pathogenesis, diagnosis and management].
2002 Feb
Automated headspace solid-phase microextraction and in-matrix derivatization for the determination of amphetamine-related drugs in human urine by gas chromatography-mass spectrometry.
2002 Jan
Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine.
2002 Jan-Feb
Reversal of Phen-Fen associated valvular regurgitation documented by serial echocardiography.
2002 Jun
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
2002 Jun 15
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine.
2002 Jun 7
Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine.
2002 Mar
Phentermine inhibition of recombinant human liver monoamine oxidases A and B.
2002 Mar 1
Regression and progression of valvulopathy associated with fenfluramine and phentermine.
2002 Mar 19
I have tried everything I can think of to lose weight on my own and am now thinking of using weight-loss medications. Are they safe?
2002 May
Prevalence of drug use in commercial tractor-trailer drivers.
2002 May
Diet medications and valvular heart disease: the current evidence.
2002 May-Jun
Enantiomeric separation of methamphetamine and related analogs by capillary zone electrophoresis: intelligence study in routine methamphetamine seizures.
2002 Nov
Appetite suppressants and valvular heart disease.
2002 Sep
Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects.
2002 Sep
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion?
2002 Sep-Oct
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
2003 Apr
Anorexigen-induced cardiac valvulopathy and female gender.
2003 Apr
Noradrenergic modulation of ephedrine-induced hypophagia.
2003 Apr
Effects of tyrosine, phentermine, caffeine D-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation.
2003 Aug
A comparison of tyrosine against placebo, phentermine, caffeine, and D-amphetamine during sleep deprivation.
2003 Aug
Obesity.
2003 Dec
Ischemic colitis after weight-loss medication.
2003 Dec
The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux.
2003 Dec
Internet pharmacy prescription and phentermine overdose.
2003 Feb
Treatment of obesity: an update on anti-obesity medications.
2003 Feb
Medical monitoring for pharmaceutical injuries: tort law for the public's health?
2003 Feb 19
Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats.
2003 Jul 5
Risk of valvular heart disease associated with use of fenfluramine.
2003 Jun 11
Postmarketing surveillance of abuse liability of sibutramine.
2003 Mar 1
National trends in antiobesity medication use.
2003 May 12
Malpractice. Conviction upheld for doctor who treated AIDS with fen/phen.
2003 May 9
Obesity: an overview on its current perspectives and treatment options.
2004 Apr 14
The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment.
2004 Dec
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.
2004 Dec
Going before disciplinary board without counsel is unwise. Case on point: Slone-Vasquez v. Kentucky Board Of Nursing, 2003 WL 22976179 S.W.3d-KY.
2004 Jan
Pharmacological and surgical treatment of obesity.
2004 Jul
Relationship between collagen fibrils, glycosaminoglycans, and stress relaxation in mitral valve chordae tendineae.
2004 Jul
Obesity.
2004 Jun
The long-term management of obesity with continuing pharmacotherapy.
2004 Nov
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
2005 Jan 25
Effects of phentermine and phenformin on biomarkers of aging in rats.
2005 Jan-Feb
Acute nonarteritic ischaemic optic neuropathy after phentermine.
2005 Nov
Patents

Sample Use Guides

Usual Adult Dose for Weight Loss 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast. Usual Pediatric Dose for Weight Loss 17 years or older: 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Route of Administration: Oral
Phentermine inhibited serotonin-metabolizing (MAO-A) activity in rat lung, brain, and liver with K(i) values of 85-88 uM.
Name Type Language
PHENTERMINE
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
PHENTERMINE [WHO-DD]
Common Name English
PHENTERMINE [VANDF]
Common Name English
NSC-759163
Code English
PHENTERMINE [HSDB]
Common Name English
QSIVA
Brand Name English
PHENTERMINE [MART.]
Common Name English
BENZENEETHANAMINE, .ALPHA.,.ALPHA.-DIMETHYL-
Systematic Name English
PHENTERMINE [USAN]
Common Name English
DUROMINE
Brand Name English
PHENTERMINE [INN]
Common Name English
PHENTERMINE [MI]
Common Name English
.ALPHA.,.ALPHA.-DIMETHYLPHENETHYLAMINE
Systematic Name English
PHENTERMINE COMPONENT OF QSYMIA
Brand Name English
QSYMIA COMPONENT PHENTERMINE
Brand Name English
IONAMIN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175651
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
WHO-VATC QA08AA01
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
NDF-RT N0000175423
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
DEA NO. 1640
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
NCI_THESAURUS C29728
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
WHO-ATC A08AA01
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
EMA ASSESSMENT REPORTS QSIVA (REFUSED: OBESITY)
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
LIVERTOX 772
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
NDF-RT N0000175372
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
NDF-RT N0000175372
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
204-522-1
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
INN
1064
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL1574
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
MERCK INDEX
M8644
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY Merck Index
EVMPD
SUB09784MIG
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
HSDB
3158
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
NCI_THESAURUS
C61890
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
WIKIPEDIA
PHENTERMINE
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
PUBCHEM
4771
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
RXCUI
8152
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
FDA UNII
C045TQL4WP
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
DRUG BANK
DB00191
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
MESH
D010645
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
CAS
122-09-8
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
IUPHAR
7269
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
DRUG CENTRAL
2140
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY
EPA CompTox
122-09-8
Created by admin on Fri Jun 25 21:55:21 UTC 2021 , Edited by admin on Fri Jun 25 21:55:21 UTC 2021
PRIMARY